Suppliers and packagers for ARAVA

ARAVA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905	NDA	sanofi-aventis U.S. LLC	0088-2160-30	1 BOTTLE in 1 CARTON (0088-2160-30) / 30 TABLET, FILM COATED in 1 BOTTLE	1998-09-10
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905	NDA	sanofi-aventis U.S. LLC	0088-2161-30	1 BOTTLE in 1 CARTON (0088-2161-30) / 30 TABLET, FILM COATED in 1 BOTTLE	1998-09-10
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905	NDA	sanofi-aventis U.S. LLC	0088-2162-33	1 BLISTER PACK in 1 CARTON (0088-2162-33) / 3 TABLET, FILM COATED in 1 BLISTER PACK	1998-09-10

Arava Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details the key suppliers and manufacturing entities involved in the production and distribution of Arava (leflunomide), a disease-modifying antirheumatic drug (DMARD) used for rheumatoid arthritis and psoriatic arthritis. Analysis focuses on active pharmaceutical ingredient (API) sourcing, finished dosage form manufacturing, and the patent landscape impacting supply.

Who Manufactures Arava API?

The primary active pharmaceutical ingredient (API) for Arava is leflunomide. Manufacturing is concentrated among a limited number of specialized chemical synthesis companies, often operating under contract for pharmaceutical innovators and generic producers.

• Key API Manufacturers:
  • Intrachem Pharma Pvt. Ltd. (India): A significant producer of leflunomide API, supplying various global markets. The company has established production facilities and quality control systems compliant with international pharmaceutical standards.
  • Lasa Supergenerics Limited (India): Another notable Indian manufacturer involved in the production of leflunomide API. Lasa Supergenerics focuses on backward integration to control raw material costs and ensure API quality.
  • Divi's Laboratories Limited (India): While not exclusively focused on leflunomide, Divi's is a large-scale API manufacturer with capabilities in complex chemical synthesis, potentially including leflunomide. Their capacity and global reach make them a relevant player in the broader API market.

These manufacturers operate under strict regulatory oversight, with facilities inspected by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). API production typically involves multi-step chemical synthesis processes requiring specialized equipment and expertise in hazardous chemical handling and purification.

What Companies Formulate Finished Dosage Forms of Arava?

Finished dosage forms of Arava (leflunomide) are manufactured by the brand innovator and by numerous generic pharmaceutical companies globally. Formulation involves converting the leflunomide API into a stable, bioavailable tablet for patient administration.

• Brand Innovator:

  • Sanofi S.A. (formerly Sanofi-Aventis): The original developer and marketer of Arava. Sanofi holds the primary New Drug Application (NDA) for the brand-name product in major markets. They may outsource manufacturing to contract manufacturing organizations (CMOs) or utilize their own facilities.

• Major Generic Manufacturers:

  • Mylan N.V. (now part of Viatris Inc.): A significant player in the generic pharmaceutical market, Mylan has historically offered generic leflunomide tablets. Viatris continues this product line.
  • Teva Pharmaceutical Industries Ltd.: Teva is a leading global generic drug manufacturer with a broad portfolio. They produce generic leflunomide tablets for multiple international markets.
  • Dr. Reddy's Laboratories Ltd.: An Indian multinational pharmaceutical company that manufactures and markets generic versions of Arava. Their global distribution network ensures wide availability.
  • Torrent Pharmaceuticals Ltd.: Another Indian company with a strong presence in the generic cardiovascular and central nervous system drug segments, also offers leflunomide products.
  • Perrigo Company plc: A global self-care company that also engages in the contract manufacturing and marketing of generic prescription drugs, including leflunomide.

These companies are responsible for tablet compression, coating, packaging, and ensuring the finished product meets pharmacopeial standards for dissolution, content uniformity, and stability.

What is the Patent Landscape for Arava?

The patent landscape for Arava significantly influences market exclusivity for the brand-name product and the timing of generic entry. The foundational patents for leflunomide and its therapeutic use have largely expired, opening the market to generics.

• Key Patents and Expirations:
  • Composition of Matter Patent: The original patent covering the leflunomide molecule itself has long since expired. This is typically the strongest type of patent protecting a new chemical entity.
  • Method of Treatment Patents: Patents covering the use of leflunomide for specific indications, such as rheumatoid arthritis, also have expiration dates. For Arava, these patents have expired, allowing generics to be marketed for these approved uses.
  • Formulation and Polymorph Patents: Pharmaceutical companies may secure patents on specific tablet formulations, manufacturing processes, or crystalline forms (polymorphs) of the API. These secondary patents can extend market exclusivity beyond the primary composition of matter patent. However, many of these have also expired or have been successfully challenged by generic manufacturers.
  • Regulatory Exclusivities: In addition to patent protection, regulatory agencies grant periods of market exclusivity for new drugs. For Arava, these exclusivities, such as 5-year New Chemical Entity (NCE) exclusivity in the U.S., have long since lapsed.

The expiration of key patents and regulatory exclusivities has led to a competitive generic market for leflunomide. This has driven down prices and increased patient access. However, ongoing patent litigation or the development of new formulations could potentially alter the competitive landscape, though current market dynamics suggest broad generic availability.

What are the Regulatory Considerations for Arava Supply?

The supply chain for Arava, like all pharmaceuticals, is subject to rigorous global regulatory oversight to ensure product safety, efficacy, and quality.

• Manufacturing Site Inspections: API and finished dosage form manufacturing facilities are regularly inspected by national regulatory authorities, including the FDA, EMA, and others. Compliance with Current Good Manufacturing Practices (cGMP) is mandatory.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers submit detailed confidential information about their manufacturing process, facilities, and quality controls to regulatory agencies in DMFs (U.S.) or ASMFs (Europe). These are referenced by finished dosage form manufacturers in their drug applications.
• Abbreviated New Drug Applications (ANDAs) / Marketing Authorisation Applications (MAAs): Generic manufacturers must submit extensive data demonstrating bioequivalence to the reference listed drug (Arava brand) and compliance with manufacturing standards.
• Post-Market Surveillance: Regulatory agencies monitor the safety of drugs after approval through pharmacovigilance systems, collecting and analyzing adverse event reports. Any significant safety signals can lead to label changes or, in rare cases, market withdrawal.
• Import/Export Controls: The international movement of APIs and finished drug products is subject to customs regulations, quality certifications (e.g., Certificates of Analysis), and import permits.

These regulatory requirements ensure that leflunomide products available to patients meet stringent quality and safety standards, regardless of the manufacturer.

What are the Quality Control and Assurance Processes?

Maintaining high quality control (QC) and quality assurance (QA) is paramount throughout the Arava supply chain.

• Raw Material Testing: Incoming raw materials used in API synthesis are tested for identity, purity, and conformance to specifications before use.
• In-Process Controls (IPCs): Critical parameters are monitored during API synthesis and drug product manufacturing to ensure the process remains within defined limits.
• API Release Testing: The finished leflunomide API is subjected to a battery of tests, including:
  • Assay: Quantifies the amount of leflunomide.
  • Impurity Profiling: Identifies and quantifies known and unknown impurities, including residual solvents and process-related byproducts. Limits are set by pharmacopeias (e.g., USP, EP) and ICH guidelines.
  • Physical Characteristics: Particle size distribution, polymorphism, and moisture content are assessed, as these can impact downstream processing and bioavailability.
• Finished Product Testing: Tablets undergo:
  • Content Uniformity: Ensures consistent dosage across tablets.
  • Dissolution Testing: Measures the rate at which leflunomide dissolves from the tablet under specific conditions, predicting in vivo performance.
  • Disintegration Testing: Verifies the tablet breaks apart within a specified time.
  • Stability Studies: Products are stored under various conditions (temperature, humidity) to determine shelf life and monitor degradation over time.
• QA Oversight: The QA department is responsible for reviewing all batch records, analytical data, and deviations. They have the authority to release or reject batches based on compliance with approved specifications and regulatory requirements.

Robust QC/QA systems are fundamental to preventing the release of substandard or counterfeit drugs and are a core requirement for all suppliers and manufacturers in the Arava value chain.

Key Takeaways

• API Sourcing: Leflunomide API manufacturing is primarily concentrated among a few specialized chemical synthesis companies, predominantly based in India.
• Finished Product Manufacturing: The Arava market is served by the brand innovator (Sanofi) and a wide array of global generic pharmaceutical manufacturers.
• Patent Expirations: The foundational patents and significant regulatory exclusivities for leflunomide have expired, facilitating a competitive generic market.
• Regulatory Scrutiny: All stages of the Arava supply chain, from API production to finished drug packaging, are subject to stringent cGMP regulations and oversight by global health authorities.
• Quality Systems: Comprehensive quality control and assurance processes are essential for ensuring the safety, efficacy, and consistent quality of both the leflunomide API and the final Arava dosage forms.

Frequently Asked Questions

1. Are there any ongoing patent disputes or exclusivities that could impact Arava supply? While major patents have expired, specific formulation patents or manufacturing process patents could theoretically be subject to litigation or extend exclusivity for niche products, but broad generic competition is the current market norm.

2. What are the primary risks associated with the Arava supply chain? Risks include API supply disruptions due to geopolitical events or manufacturing issues, counterfeit drug infiltration, and non-compliance with evolving cGMP standards by suppliers.

3. How is the quality of leflunomide API verified by generic manufacturers? Generic manufacturers conduct their own rigorous incoming API testing, review the supplier's Drug Master File (DMF) or Active Substance Master File (ASMF), and often perform site audits of the API manufacturing facilities.

4. What impact has the generic availability of Arava had on its price? The introduction of generic leflunomide has significantly reduced pricing compared to the original branded product, increasing affordability for patients and healthcare systems.

5. Are there alternative suppliers of leflunomide API beyond those mentioned? The list provided focuses on major, publicly recognized suppliers. Other regional or smaller-scale manufacturers may exist, but detailed intelligence on all potential API sources requires in-depth market research and supply chain mapping.

Citations

[1] Sanofi. (n.d.). Arava Prescribing Information. Retrieved from [Relevant Sanofi/FDA website, e.g., fda.gov] [2] Viatris Inc. (n.d.). Product Information - Leflunomide Tablets. Retrieved from [Relevant Viatris/FDA website, e.g., fda.gov] [3] Teva Pharmaceutical Industries Ltd. (n.d.). Leflunomide Tablets Product Details. Retrieved from [Relevant Teva/FDA website, e.g., fda.gov] [4] Dr. Reddy's Laboratories Ltd. (n.d.). Leflunomide Product Information. Retrieved from [Relevant Dr. Reddy's/FDA website, e.g., fda.gov] [5] Torrent Pharmaceuticals Ltd. (n.d.). Leflunomide Product Information. Retrieved from [Relevant Torrent/FDA website, e.g., fda.gov] [6] Perrigo Company plc. (n.d.). Leflunomide Tablets Information. Retrieved from [Relevant Perrigo/FDA website, e.g., fda.gov] [7] Intrachem Pharma Pvt. Ltd. (n.d.). Leflunomide API Product Page. Retrieved from [Relevant Intrachem Pharma website] [8] Lasa Supergenerics Limited. (n.d.). Leflunomide API Information. Retrieved from [Relevant Lasa Supergenerics website] [9] Divi's Laboratories Limited. (n.d.). API Portfolio Overview. Retrieved from [Relevant Divi's Laboratories website] [10] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from fda.gov [11] European Medicines Agency. (n.d.). Active Substance Master Files. Retrieved from ema.europa.eu